Ken Griffin Anixa Biosciences Inc Transaction History

Citadel Advisors LLC

$505 Billion
Q3 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Anixa Biosciences Inc stock. As of the latest transaction made, Citadel Advisors LLC holds 21,000 shares of ANIX stock, worth $58,799. This represents 0.0% of its overall portfolio holdings.

Number of Shares

21,000

Holding current value

$58,799

% of portfolio

0.0%

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$2.21 - $3.48 $12,563 - $19,783	5,685 New	5,685 $17,000
Q1 2024 May 15, 2024	BUY	$3.08 - $5.02 $66,401 - $108,226	21,559 Added 129.13%	38,254 $119,000
Q4 2023 Feb 14, 2024	SELL	$2.85 - $4.19 $68,058 - $100,057	-23,880 Reduced 58.85%	16,695 $64,000
Q3 2023 Nov 14, 2023	SELL	$2.97 - $3.87 $6,287 - $8,192	-2,117 Reduced 4.96%	40,575 $132,000
Q2 2023 Aug 14, 2023	BUY	$3.0 - $5.97 $94,434 - $187,923	31,478 Added 280.7%	42,692 $136,000
Q1 2023 May 15, 2023	SELL	$3.86 - $5.0 $140,087 - $181,460	-36,292 Reduced 76.39%	11,214 $48,000
Q4 2022 Feb 14, 2023	BUY	$3.78 - $5.81 $105,446 - $162,075	27,896 Added 142.25%	47,506 $201,000
Q3 2022 Nov 14, 2022	SELL	$2.81 - $6.15 $13,162 - $28,806	-4,684 Reduced 19.28%	19,610 $97,000
Q2 2022 Aug 15, 2022	BUY	$2.55 - $4.1 $61,949 - $99,605	24,294 New	24,294 $74,000
Q1 2022 May 16, 2022	SELL	$2.5 - $3.42 $84,837 - $116,057	-33,935 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$2.88 - $5.5 $56,669 - $108,223	19,677 Added 138.01%	33,935 $100,000
Q3 2021 Nov 15, 2021	SELL	$3.57 - $5.6 $19,363 - $30,374	-5,424 Reduced 27.56%	14,258 $68,000
Q1 2021 May 17, 2021	BUY	$3.27 - $7.14 $16,951 - $37,013	5,184 Added 35.76%	19,682 $92,000
Q4 2020 Feb 16, 2021	BUY	$1.94 - $3.19 $28,126 - $46,248	14,498 New	14,498 $45,000

Others Institutions Holding ANIX

# of Institutions

Shares Held

5.56M

Call Options Held

21K

Put Options Held

6.7K

View Full List

About Anixa Biosciences Inc

Ticker ANIX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 30,661,700
Market Cap $85.9M
Description
Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell technology, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the...

More about ANIX

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account